NasdaqGM:AXSMPharmaceuticals
The Bull Case For Axsome Therapeutics (AXSM) Could Change Following Rising Revenue And Widening Net Losses
Axsome Therapeutics, Inc. has reported past results for the second quarter and first half of 2026, with quarterly revenue of US$218.38 million and a net loss of US$51.31 million, and six‑month revenue of US$409.58 million and a net loss of US$115.86 million.
While Axsome’s revenue increased compared with the prior year periods, its losses and loss per share also widened, underscoring the cost of expanding its central nervous system portfolio and commercialization efforts.
We’ll now examine...